Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial

This is a phase II dose escalation trial of carfilzomib in combination with thalidomide and dexamethasone for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The results of four dose levels are reported. Induction therapy consisted of four cy...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ruth Wester, Bronno van der Holt, Emelie Asselbergs, Sonja Zweegman, Marie Jose Kersten, Edo Vellenga, Marinus van Marwijk Kooy, Okke de Weerdt, Monique Minnema, Sarah Lonergan, Antonio Palumbo, Henk Lokhorst, Annemiek Broijl, Pieter Sonneveld
Format:	Artigo
Idioma:	Inglês
Publicat:	Ferrata Storti Foundation 2019-11-01
Col·lecció:	Haematologica
Accés en línia:	https://haematologica.org/article/view/9129
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!